Medicilon Assists YY201 successfully completed dual submissions in China and US
Medicilon
  • Reads 1
  • Votes 0
  • Parts 1
  • Time <5 mins
  • Reads 1
  • Votes 0
  • Parts 1
  • Time <5 mins
Medicilon
Ongoing, First published Dec 08, 2023
stat3
Recently, YY201, a STAT3 dual phosphorylation site inhibitor independently developed by Yuyao Biotech, was approved by the US FDA and agreed to conduct Phase I clinical studies for malignant hematological tumors.  This is another milestone after YY201 IND was approved by China's NMPA in July 2023. It is also an important step for Yuyao Biotech to move towards globalization and international development with its independently built first-class technology platform and leading product pipeline.
All Rights Reserved
stat3
Table of contents

1 part

Sign up to add Medicilon Assists YY201 successfully completed dual submissions in China and US to your library and receive updates
or
Content Guidelines
You may also like
The Hidden Shadow by OutOfMyLimit17
42 parts Complete
A million dollar bounty, underground assassins, torture-it's all in a days work for assassin Jessie Wright. * * * * * * Molded into an assassin by the one who killed her parents, Jessie defies orders and goes rogue. Now with a bounty on her head, her only chance of survival may be with a man who's reputation is worse than her own. Violence, Assault, Swearing.
You may also like
Slide 1 of 1
The Hidden Shadow cover

The Hidden Shadow

42 parts Complete

A million dollar bounty, underground assassins, torture-it's all in a days work for assassin Jessie Wright. * * * * * * Molded into an assassin by the one who killed her parents, Jessie defies orders and goes rogue. Now with a bounty on her head, her only chance of survival may be with a man who's reputation is worse than her own. Violence, Assault, Swearing.

More details